

1 **Spike protein antibodies mediate the apparent correlation between**
2 **SARS-CoV-2 nucleocapsid antibodies and neutralization test**
3 **results**

4 THOMAS PERKMANN¹, THOMAS KOLLER¹, NICOLE PERKMANN-NAGELE¹, MIRIAM KLAUSBERGER², MARK
5 DUERKOP³, BARBARA HOLZER⁴, BORIS HARTMANN⁴, PATRICK MUCHER¹, ASTRID RADAKOVICS¹, MARIA
6 OZSVAR-KOZMA¹, OSWALD F WAGNER¹, CHRISTOPH J BINDER¹, AND HELMUTH HASLACHER^{1*}

7
8 ¹DEPARTMENT OF LABORATORY MEDICINE, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

9 ²INSTITUTE OF MOLECULAR BIOTECHNOLOGY, DEPARTMENT OF BIOTECHNOLOGY, UNIVERSITY OF NATURAL
10 RESOURCES AND LIFE SCIENCES (BOKU) VIENNA, AUSTRIA

11 ³INSTITUTE OF BIOPROCESS SCIENCE AND ENGINEERING, DEPARTMENT OF BIOTECHNOLOGY, UNIVERSITY OF
12 NATURAL RESOURCES AND LIFE SCIENCES (BOKU) VIENNA, AUSTRIA

13 ⁴DEPARTMENT FOR ANIMAL HEALTH, AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY (AGES), MOEDLING,
14 AUSTRIA

15
16 * CORRESPONDING AUTHOR:

17 HELMUTH HASLACHER, LECT MD PHD MSC BSC BA

18 MEDICAL UNIVERSITY OF VIENNA

19 DEPARTMENT OF LABORATORY MEDICINE

20 WAEHRINGER GUERTEL 18-20

21 1090 VIENNA, AUSTRIA

22 HELMUTH.HASLACHER@MEDUNIWIEN.AC.AT

23 PHONE: +43 1 40400 53190, FAX: +43 1 40495 15547

24 **Abstract**

25 **Objectives**

26 SARS-CoV-2 infection induces the formation of different antibodies. However, not all of
27 which might prevent the virus from entering the cell, although their concentrations correlate
28 with the titers of viral neutralization tests (NTs). Antibodies against the viral nucleocapsid
29 (NC), e.g., can be classified as such. We aimed to prove the hypothesis that the apparent
30 correlation between NC-antibody levels and NT-titers is mediated by simultaneously
31 occurring antibodies against viral spike-protein components.

32 **Methods**

33 We included 64 individuals with previous SARS-CoV-2 infection (>14d after symptom onset).
34 SARS-CoV-2 antibodies against the NC (Roche total antibody ECLIA, Abbott IgG CMIA) and
35 spike-protein (Technozym RBD ELISA, DiaSorin S1/S2 CLIA) were measured, and
36 neutralization tests were performed. The effect of spike-protein antibodies on the
37 correlation between NC-antibodies and NT-titers was evaluated by partial correlation and
38 mediation analyses.

39 **Results**

40 Both tested assays assessing antibodies against the NC correlated significantly with NT titers:
41 Abbott $\rho=0.742$, $P<0.0001$; Roche $\rho=0.365$, $P<0.01$. However, when controlling the rank
42 correlations for the presence of RBD or S1/S2 antibodies, correlation coefficients dropped to
43 $\rho=0.318/\rho=0.329$ ($P<0.05/P<0.01$), respectively for Abbott and vanished for Roche. As a
44 result, only a maximum of 11% of NT titer variability could be explained by NC-antibody
45 levels.

46 **Conclusions**

47 Our data suggest that the apparent correlation between NC antibodies and NT titers is
48 strongly mediated by co-occurring RBD antibody concentrations. To avoid falsely implied
49 causal relationships, all correlation analyses of non-spike-associated antibody assays and
50 neutralization assays should include a partial correlation analysis to exclude a possible
51 mediator effect of spike-associated antibodies.

52 Introduction

53 Since the start of vaccinations against SARS-CoV-2, antibodies directed against the virus have
54 been in the spotlight. Although the virus contains several immunogenic compounds that
55 cause antibody production, not all of them act as neutralizing antibodies, i.e. antibodies
56 which have the capacity to prevent the virus from entering host cells.
57 Specifically, antibodies against the viral spike protein, which also contains the receptor-
58 binding domain (RBD), exhibit neutralizing properties (1). Therefore, current vaccination
59 strategies aim to achieve immunity using spike protein components.
60 Additionally, some authors have shown that antibodies against the nucleocapsid protein
61 (NC) correlate with neutralization activity as well. However, these structures are not present
62 on the viral surface (2-4). Consequently, it has been hypothesized that these are mere
63 spurious correlations mediated by the co-occurrence of antibodies to RBD (2, 5).

64 Methods

65 To support this hypothesis, we measured levels of antibodies binding to the viral
66 nucleocapsid antigen in 64 individuals with previous SARS-CoV-2 infection (either PCR-
67 confirmed or symptomatic close contacts; sampling >14 days after symptom onset). We
68 used various CE-labeled immunoassays (Roche total antibody ECLIA, Abbott IgG MCLIA) and
69 antibodies to spike protein targets (Technozym RBD IgG ELISA, DiaSorin S1/S2 IgG CLIA).
70 The sera's functional ability to neutralize SARS-CoV-2 viruses was tested using a classical
71 TCID50 assay (NT) as previously described (6) with the modification that the heat-treated
72 sera were diluted 1:4 in triplicates in serum-free HEPES-buffered DMEM medium. To
73 quantify neutralization titer, the reciprocal of the highest serum dilution that protected

74 more than 50% of the cells from the cytopathic effect was used and was calculated
75 according to Reed and Muench (7).
76 Recruiting procedures, pre-analytical workflows and analytical methods were reported
77 earlier (8-10). Samples were either left-over materials from the General Hospital Vienna or
78 donated by convalescent donors giving written informed consent (EK 2011/404). This
79 evaluation is part of a study which was reviewed and approved by the ethics committee of
80 the Medical University of Vienna (EK 2257/2020).
81 As data did not meet the assumptions for parametric testing, all statistical analyses were
82 performed on ranks. To test whether a correlation is disturbed by a mediator (e.g. RBD or
83 S1/S2 antibody concentrations), partial rank correlation tests and mediation analyses,
84 according to Hayes (11) were performed. The latter uses ordinary least squares regression,
85 whereby confidence intervals were computed by bootstrapping with 5000 samples. In brief,
86 the mediation analysis quantifies the total effect of NC antibody levels on NT titers (c), as
87 well as the direct effect of NC antibody levels on NT titers (c') after subtracting the
88 mediation effect of co-occurring RBD antibody concentrations.

89 Results

90 Both tested assays assessing antibodies against the NC correlated significantly with NT titers:
91 Abbott $\rho=0.742$, $P=2.2 \times 10^{-12}$; Roche $\rho=0.365$, $P=0.003$. However, if the rank correlations
92 were controlled for RBD antibodies' presence, correlation coefficients dropped to $\rho=0.318$
93 ($P=0.011$, Abbott), $\rho=0.032$ ($P=0.806$, Roche). The same holds if antibodies against an S1/S2
94 combination antigen were kept constant: $\rho=0.329$ ($P=0.008$, Abbott), $\rho=-0.101$ ($P=0.430$,
95 Roche). When RBD or S1/S2 antibody concentrations were not considered, up to 55% of NT
96 titers' variability could be explained by NC antibody concentrations (Abbott). However, after

97 introducing RBD or S1/S2 antibody concentrations as a mediator variable, only a maximum
98 of 11% of NT titer variability could be explained by NC antibody levels (see Figure 1).
99 This association was also evident in a mediation analysis on ranks. Both NC assays
100 significantly predicted NT titers (Abbott: $B=0.74$, $P<0.0001$; Roche: $B=0.36$, $P=0.002$). After
101 including Technozym RBD IgG concentrations as a mediator into the model, the effect of
102 Abbott NC IgG levels on NT titers were partly mediated (indirect effect $ab=0.46$, 95%CI: 0.27
103 – 0.73) and the relationship between Roche NC total antibody levels and NT titers was fully
104 mediated ($ab=0.34$, 95%CI: 0.17 – 0.53) by the RBD IgG concentrations (see Figure 1).
105 In a last step, we aimed to assess whether the correlation between RBD antibody
106 concentrations and NT titers could be attenuated to the same extent by keeping NC
107 antibody concentrations constant. Although controlling for Abbott NC IgG-levels affected the
108 coefficients of determination, the remaining R^2 was still 0.31 for S1/S2 and 0.35 for RBD
109 antibodies (see Figure 2).

110 Conclusions

111 Our data suggest that the relationship between NC antibody levels and NT titers is only
112 apparent and is mostly mediated by the concomitant presence of RBD or S1/S2 antibodies.
113 Spike protein specific antibody concentrations and NT titers remain correlated after keeping
114 NC antibody levels constant. In contrast, the correlation between NC antibody levels and NT
115 titers nearly vanished for most of the assessed test systems after keeping RBD or S1/S2
116 antibody levels constant. This was especially true for Roche NC-assay measured total NC
117 antibody levels, whereas the IgG-based assays appeared to correlate better with NT titers.
118 The remaining weak correlation between the Abbott test results and the NT titers, while

119 keeping RBD- or S1/S2 IgG antibody concentrations constant, suggests that a third mediator
120 variable may be present.

121 To prevent falsely implied causal relationships between SARS-CoV-2 specific NC antibodies
122 and neutralizing activity, all correlation analyses of non-spike-associated antibody assays and
123 neutralization assays should include a partial correlation analysis to exclude a possible
124 mediator effect of spike-associated antibodies.

125 Acknowledgements

126 This study was conducted in cooperation with the MedUni Wien Biobank facility. We thank
127 all sample donors for their contribution, as well as Miss Manuela Repl and Miss Marika
128 Gerdov for perfect technical assistance.

129 References







- 130 1. Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Structural Basis of SARS-CoV-2
131 and SARS-CoV Antibody Interactions. *Trends Immunol.* 2020;41(11):1006-22.
- 132 2. Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C, et al.
133 Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of
134 patients with mild COVID-19: clinical sensitivity, specificity and association with virus
135 neutralization test. *Clin Chem.* 2021.
- 136 3. Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, Schmit J-L, et al. Anti-spike,
137 Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic
138 Individuals. *Frontiers in Microbiology.* 2020;11(2468).

- 139 4. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association
140 between SARS-CoV-2 neutralizing antibodies and commercial serological assays. *Clin Chem*.
141 2020.
- 142 5. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al.
143 Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and
144 nucleocapsid with implications for COVID-19 immunity. *JCI Insight*. 2020;5(18).
- 145 6. Laferl H, Kelani H, Seitz T, Holzer B, Zimpernik I, Steinrigl A, et al. An approach to
146 lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA.
147 *Infection*. 2020.
- 148 7. REED LJ, MUENCH H. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT
149 ENDPOINTS¹². *American Journal of Epidemiology*. 1938;27(3):493-7.
- 150 8. Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC,
151 Hartl S, et al. Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody
152 Assays with a Focus on Specificity. *Clin Chem*. 2020;66(11):1405-13.
- 153 9. Perkmann T, Perkmann-Nagele N, Oszvar-Kozma M, Koller T, Breyer M-K, Breyer-
154 Kohansal R, et al. Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by
155 using an adaptive orthogonal testing approach. *medRxiv*. 2020:2020.11.05.20226449.
- 156 10. Haslacher H, Gerner M, Hofer P, Jurkowitsch A, Hainfellner J, Kain R, et al. Usage Data
157 and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-
158 Based MedUni Wien Biobank. *Biopreserv Biobank*. 2018;16(6):477-82.
- 159 11. Hayes AF. *Introduction to Mediation, Moderation, and Conditional Process Analysis*.
160 2nd Ed. ed. New York: Guilford Press; 2018.

161 Captions to figures

162 **Figure 1:** Rank correlations between titers of viral neutralization tests (NT) and nucleocapsid
163 antibody concentrations measured by the a) Abbott CMIA (IgG) or the b) Roche ECLIA (IgG,
164 IgM, IgA). The figures in the second column show the changes in rank correlations by
165 keeping the RBD (Technozym) or S1/S2 (DiaSorin) IgG antibody concentration constant,
166 respectively. c) mediation analysis to assess whether the effect of Abbott nucleocapsid (NC)
167 IgG levels (left) or Roche NC total antibody (Ab) levels (right) on viral neutralization test (NT)
168 titers is mediated by Technozym RBD antibody concentrations. *... $P < 0.05$, **... $P < 0.01$,
169 ****... $P < 0.0001$, R^2 ... Coefficient of determination, c ... total effect, c' ... direct effect of NC
170 antibody levels on NT titer.

171 **Figure 2:** Rank correlations between titers of viral neutralization tests (NT) and a) RBD
172 antibody concentrations quantified by the Technozym RBD ELISA or b) S1/S2 antibodies. The
173 figures in the second and third column present rank correlations between NT and RBD with
174 anti-nucleocapsid antibody concentrations kept constant in two different assays (Abbott,
175 Roche). R^2 ... Coefficient of determination.



c

